Clinical Trial: D910GC00001

Trial Status: Open
Disease Type: Esophageal/Gastric
Trial ID D910GC00001
Sponsor ID Matterhorn

A Randomized, Double Blind, Placebo-Controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy in Patients with Resectable Gastric and GE Junction Cancer

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID PCS6422G1-01
Sponsor ID Processa

A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

Trial ID D967LC00001
Sponsor ID DESTINY-Gastric03

A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer